Raymond James Trust N.A. Has $266,000 Stake in Regeneron Pharmaceuticals Inc (REGN)

Raymond James Trust N.A. lessened its position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 28.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 649 shares of the biopharmaceutical company’s stock after selling 255 shares during the period. Raymond James Trust N.A.’s holdings in Regeneron Pharmaceuticals were worth $266,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of REGN. BlackRock Inc. increased its position in Regeneron Pharmaceuticals by 1.1% during the fourth quarter. BlackRock Inc. now owns 5,929,225 shares of the biopharmaceutical company’s stock worth $2,214,564,000 after purchasing an additional 67,241 shares during the last quarter. Vanguard Group Inc. increased its position in Regeneron Pharmaceuticals by 1.3% during the third quarter. Vanguard Group Inc. now owns 5,754,927 shares of the biopharmaceutical company’s stock worth $2,325,220,000 after purchasing an additional 75,868 shares during the last quarter. Vanguard Group Inc increased its position in Regeneron Pharmaceuticals by 1.3% during the third quarter. Vanguard Group Inc now owns 5,754,927 shares of the biopharmaceutical company’s stock worth $2,325,220,000 after purchasing an additional 75,868 shares during the last quarter. FMR LLC increased its position in Regeneron Pharmaceuticals by 6.6% during the fourth quarter. FMR LLC now owns 5,347,376 shares of the biopharmaceutical company’s stock worth $1,997,245,000 after purchasing an additional 330,875 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in Regeneron Pharmaceuticals by 7.8% during the fourth quarter. Geode Capital Management LLC now owns 1,078,453 shares of the biopharmaceutical company’s stock worth $402,138,000 after purchasing an additional 78,143 shares during the last quarter. 66.97% of the stock is owned by institutional investors and hedge funds.

Several brokerages recently commented on REGN. Cowen reaffirmed a “hold” rating and set a $385.00 price target on shares of Regeneron Pharmaceuticals in a research report on Monday, January 7th. Piper Jaffray Companies upped their price target on shares of Regeneron Pharmaceuticals to $487.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 26th. BidaskClub raised shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, March 1st. Zacks Investment Research lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, February 8th. Finally, TheStreet raised shares of Regeneron Pharmaceuticals from a “c+” rating to a “b” rating in a research report on Thursday, January 17th. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Regeneron Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $413.94.

REGN opened at $333.34 on Monday. The company has a quick ratio of 3.67, a current ratio of 4.47 and a debt-to-equity ratio of 0.08. Regeneron Pharmaceuticals Inc has a 52-week low of $281.89 and a 52-week high of $442.00. The company has a market cap of $36.43 billion, a price-to-earnings ratio of 16.84, a price-to-earnings-growth ratio of 1.29 and a beta of 1.18.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Wednesday, February 6th. The biopharmaceutical company reported $6.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.10 by $1.74. Regeneron Pharmaceuticals had a net margin of 36.43% and a return on equity of 29.77%. The company had revenue of $1.93 billion during the quarter, compared to the consensus estimate of $1.73 billion. During the same period in the previous year, the firm earned $5.23 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 21.9% on a year-over-year basis. On average, research analysts predict that Regeneron Pharmaceuticals Inc will post 19.92 earnings per share for the current fiscal year.

In other Regeneron Pharmaceuticals news, major shareholder Sanofi sold 131,115 shares of the business’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $412.17, for a total transaction of $54,041,669.55. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 12.42% of the stock is owned by insiders.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://www.baseballdailydigest.com/news/2019/04/22/raymond-james-trust-n-a-has-266000-stake-in-regeneron-pharmaceuticals-inc-regn.html.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Story: What is a Market Correction?

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.